The Russian pharmaceutical company Avexima has started construction of a production cluster in Esipovo Industrial Park in the Solnechnogorsk District of the Moscow Region. The management company of the Park is the Corporation for the Development of the Moscow Region. The site will provide a full production cycle of new medicines. The investments will amount to 6.5 billion rubles. The launch of the first stage is scheduled for 2027, with the full implementation of the project in 8 years, the press service of the regional Ministry of Investment, Industry and Science reported.
“In the Moscow Region, the company will develop and manufacture drugs for cardiology, endocrinology, gastroenterology, gynecology, dermatology, neurology, immunology, and oncology,” said Ivan Khalepo, Avexima’s general director.
The complex with an area of over 170,000 square meters will include laboratories and pilot production sites for a full cycle of drug development and production. It is planned to create more than 1,500 jobs at the facility.
OAO Avexima and AO Moscow Region Development Corporation signed an additional agreement to expand cooperation within the framework of an investment project for the construction of a pharmaceutical production and logistics complex in the Esipovo Industrial Park in 2021.
As Ekaterina Zinovieva, Deputy Chair of the Government of the Moscow Region, Minister of Investment, Industry and Science of the region, noted at the time, as part of the signed document, the area of the site for Avexima’s investment project will grow from 20 to 33 hectares. This will allow the investor to expand the project, which will be implemented in two stages. Investments in the project will increase from 3 billion to 6.5 billion rubles.
Avexima is a vertically integrated pharmaceutical manufacturer founded in 2011. Currently, the company has three plants: Avexima Siberia (Kemerovo region), Immafarma (Moscow), and the Irbit Chemical Pharmaceutical Plant (Sverdlovsk region).
